APA (7th ed.) Citation

2nd, P. J., ME, G., AS, B., PE, H., Z, D., L, C., . . . O, H. (2025). First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors. The oncologist, 30(7), . https://doi.org/10.1093/oncolo/oyaf136

Chicago Style (17th ed.) Citation

2nd, Powderly JD, et al. "First-in-human Phase I Open-label Study of the LAG-3 Antagonist Antibody INCAGN02385 in Patients with Select Advanced or Metastatic Solid Tumors." The Oncologist 30, no. 7 (2025). https://doi.org/10.1093/oncolo/oyaf136.

MLA (9th ed.) Citation

2nd, Powderly JD, et al. "First-in-human Phase I Open-label Study of the LAG-3 Antagonist Antibody INCAGN02385 in Patients with Select Advanced or Metastatic Solid Tumors." The Oncologist, vol. 30, no. 7, 2025, https://doi.org/10.1093/oncolo/oyaf136.